You have reached the legacy site. Please visit our new site at

 HIV and Coverage of the
17th Conference on Retroviruses and
Infections (CROI 2010)
 February 16 - 19, San Franciso, California
  The material posted on HIV and about CROI 2010 is not approved by nor is it a part of CROI 2010.
Library of Slides and Posters
HIV/AIDS Articles
HIV/HCV and HIV/HBV Coinfection Articles

    Google Custom Search
HIV/AIDS Articles
Even Low-level, Short-term Detectable Viral Load Raises the Risk of Virological Treatment Failure and Death
Vitamin D Deficiency Is Widespread Among People with HIV in U.S., Europe, and Africa
ART Intensification with Maraviroc (Selzentry) or Raltegravir (Isentress) May Improve Immune Activation and Inflammation
VIRxSYS Lentivirus Vector HIV Vaccine Reduces Viral Load in Monkey Study
Prompt Testing and Expanded Treatment Linked to Reduce HIV Incidence in San Francisco, Washington DC, and Vancouver
Early Indicators of Atherosclerosis in People with HIV Are Linked to Inflammation, Improve with Antiretroviral Therapy
Risk Factors for Neurocognitive Impairment among People with HIV
Inflammation and Immune Activation Linked to Increase Mortality Risk in People with
Elevated Inflammatory Biomarkers Are Associated with Progression to AIDS and Death despite Viral Suppression
Poor Response to Hepatitis B Vaccine Predicts HIV Disease Progression
Two European Studies Find Some People with HIV Who Start Treatment Early Can Reach Normal Life Expectancy
Daily Treatment with Valganciclovir Reduces Immune Activation in HIV Positive People with Cytomegalovirus
Chronic Kidney Disease Linked to Tenofovir (Viread) in EuroSIDA Study
HIV Infection and HIV/HCV Coinfection Increased Risk of Strokes in Veterans Study
LEDGF Integrase Inhibitors and Capsid Assembly Inhibitors Offer New Approaches for Blocking HIV Replication
ACTG 5202 Shows Abacavir/lamivudine and Tenofovir/emtricitabine Provide Similar HIV Suppression at Low Viral Loads
ACTG 5202 Sub-study Finds Lipoatrophy Uncommon, Antiretroviral Drugs Have Varying Effects on Bone and Body Fat
Early Antiretroviral Therapy Reduces HIV Transmission in Discordant Heterosexual Couples
Once-daily Boosted Darunavir (Prezista) Works as Well as Twice-daily for Treatment-experienced Patients
Quitting Smoking Lowers Risk of Cardiovascular Disease in People with HIV
HIV Raises Lung Cancer Risk, but Smoking Is a Much Stronger Predictor
Research Sheds New Light on HIV in the Gut
Investigational Drug TBR-652 Demonstrates Dual Activity against CCR5 and CCR2 Co-receptors
Treatment Intensification with Maraviroc (Selzentry) Did Not Raise CD4 Cell Counts in Small Study
Poor CD4 Cell Recovery on Antiretroviral Therapy Is Linked to Late Treatment, Leads to Adverse Outcomes
Gilead's "Quad" Pill Matches Atripla, New Booster Cobicistat (GS 9350) Looks Good with Atazanavir (Reyataz)
Does Liver Fibrosis Progress Faster in People Who Have HIV When They Acquire Hepatitis C?
The U.S. HIV Research Agenda and the Future of PEPFAR
Vicriviroc Fails to Beat Stiff Competition, Merck Will Not File for Treatment-experienced Approval
HIV/HCV and HIV/HBV Coinfection Articles
Spontaneous Clearance and Successful Treatment of Hepatitis C Linked to Better CD4 Cell Recovery
HIV/HBV Coinfected People at High Risk for Disease Progression During Antiretroviral Treatment Interruption
IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
HIV/HBV and HIV/HCV Coinfected People with Impaired Liver Function and Inflammation Have Higher Risk of Non-AIDS Death
Poor Response to Hepatitis B Vaccine Predicts HIV Disease Progression
Boys with Chronic Hepatitis B May Experience HBeAg Seroconversion and Reduced HBV Viral Load at Puberty
HIV Infection and HIV/HCV Coinfection Increased Risk of Strokes in Veterans Study
HIV/HBV and HIV/HCV Coinfected Patients in Africa Have Slower CD4 Recovery on Antiretroviral Therapy, but Not Increased Mortality
More Evidence of Rapid Liver Disease Progression in HIV/HCV Coinfected People, but Antiretroviral Therapy Lowers Risk
Abacavir (Ziagen) Does Not Compromise Effectiveness of Hepatitis C Treatment, but Zidovudine (Retrovir) May Reduce Response
Liver Toxicity in an International Cohort of HIV/HBV Coinfected Patients on Long-term Antiretroviral Therapy
Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
Leakage of Gut Bacteria Linked to Poor Hepatitis C Treatment Response in HIV/HCV Coinfected Patients
Hepatitis B Virus Genotype G Associated with Increased Fibrosis in HIV/HBV Coinfected People, but Blacks Fare Better
Hepatitis C Virus Can Survive in Syringes Up to 2 Months under Favorable Conditions
Sustained Response to Interferon Reduces both Liver-related and AIDS-related Disease and Death in HIV/HCV Coinfected Patients
Endothelial Dysfunction Is Worse in People with HIV/HCV Coinfection, but Improves with Sustained Response to Hepatitis C Treatment
HBV DNA Not Detected in Semen of Men with Chronic Hepatitis B Successfully Treated with Nucleotide Analogs
Shorter Treatment May Be Adequate for Genotype 1 Hepatitis C If Started during Acute Infection
Does Liver Fibrosis Progress Faster in People Who Have HIV When They Acquire Hepatitis C?
Library of Slides and Posters
Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks
M Valantin and others. CROI 2010.
Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy
L Niclot and others. CROI 2010.
The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of VirologicSuppression and GS-9350 is an Effective Booster
C Cohen and others. CROI 2010.
Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients:a Substudy of the ANRS 139 TRIO
A Barrail-Tran and others. CROI 2010.
The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK
K Boyd and others. CROI 2010.
Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype
M Haddad and others. CROI 2010.
The Binary Protease Inhibitor, Darunavir, Has a High Genetic Barrier to the Emergence of Resistant HIV-1 Variants
Y Koh and others. CROI 2010.
Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes
A Maiiga and others. CROI 2010.
Darunavir (DRV) concentrations exceed the Protein-corrected (PC) EC50 for wild type HIV in the semen of HIV-1 infected Men
S Taylor and others. CROI 2010.
Discovery of Potent HIV-1 Capsid Assembly Inhibitors
S Titolo and others. CROI 2010.
Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients
E Gotuzzo and others. CROI 2010.
Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up
E DeJesus and others. CROI 2010.
Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus
J Rockstroh and others. CROI 2010.
Sustained Antiretroviral Effect of Raltegravir at Week 156 in the BENCHMRK Studies, and Exploratory Analysis of Late Outcomes based on Early Virologic Responses
J Eron and others. CROI 2010.
A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults
D Brainard and others. CROI 2010.
Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth
S Nachman and others. CROI 2010.


























CROI 2010 Coverage